- Innovative treatment and diagnostic methods
We offers you solutions for accurate, reproducible and qualitatively outstanding aids for patient support and patient immobilisation.
We leverage our broad base of innovative products and services to offer the most effective, state-of-the-art radiotherapy positioning solutions. Discover how we are advancing patient care in a variety of ways by exploring the information below.
We specialises in niche products in the field of innovative diagnostics. Our focus is on new methods relating to current and future diagnosis modalities.
We are driven to provide care that cures and comforts, research that informs the world, and education that enlightens and enables future generations. We proudly stand on our rich history and use it as a platform from which to embrace discovery and change.
Through our products and by bringing planning modalities such as computer tomography (CT) and positron emission tomography (PET) closer together, we can give you access to new alternatives for optimizing cancer treatment.
We are committed to making each decision, whether related to patient care, research, education or administration, based on standards that are thoughtful, informed, honest, transparent when appropriate and always respectful of privacy.
The Innovative Medicines Initiative (IMI) is a European initiative to improve the competitive situation of the European Union in the field of pharmaceutical research. The IMI is a joint initiative (public-private partnership) of the DG Research of the European Commission, representing the European Communities, and the European Federation of Pharmaceutical Industries and Associations (EFPIA). IMI is laid out as a Joint Technology Initiative within the Seventh Framework Programme. Michel Goldman was the first executive director, from September 2009 until December 2014.
The Innovative Medicines Initiative is aimed towards removing research bottlenecks in the current drug development process. The IMI Joint Technology Initiative (IMI JTI), to be implemented by the IMI Joint Undertaking is meant to address these research bottlenecks. Its €2bn budget makes it the largest biomedical public-private partnership in the world.
A perfect, unflawed system in any business sector is virtually unachievable, and the biotechnology and therapeutics industries are no exception. Although we are innovating and making strides to end what were once thought of as incurable diseases, we still do not have one single agreed upon way of funding the research and development of drugs […]
Networking, networking, networking! Chances are, if you’re a college student, you’ve heard this before. The best way to set yourself up for success after graduation is through networking with professionals within your desired field. Of course, this is a very important step to transition from academia to the business world, but there are several other […]
Healthcare information technology (HIT) is becoming an ingrained part of the contemporary healthcare experience. Every year, new health tech startups unveil innovations designed to improve patient relationships and outcomes, but making a meaningful impact is more difficult than it may seem. Often the healthcare technology industry clashes with important legislation and regulation. The Office of […]
Biotechnology has been a traditionally risky investment. As Lori Kozlowski stated in Forbes, biotech requires large sums of money without any guaranteed outcome — a high risk for a potentially high reward. It can be difficult for investors to reconcile that risk when there are other avenues that yield a safer return on investment. Although […]
With the evolving digital landscape and its impact on the technology sector, innovation has become a buzzword for many different categories. Within the saturated landscape, it’s important to take a step back and think about what truly defines innovation. It’s more than the ability to take a concept and bring it to commercialization and it’s […]
Click on the image below to zoom or download our latest press release!
IDvet offers both a nucleoprotein-based cELISA to detect antibodies against all Influenza strains, and serotype-specific cELISAs to detect potentially highly-pathogenic H5 and H7 strains. To monitor outbreaks with these kits: • Flocks found positive with the nucleoprotein cELISA are tested with the H5 or H7 ELISA. • Positive H5 or H7 results are confirmed by […]
The use of recombinant proteins in the ID Screen® MG and MS ELISAs allows for improved specificity, low background, earlier detection of seroconversion, and higher analytical sensitivity. In addition, no cross-reactions with other mycoplasmas have been detected. Freeze-dried positive and negative reference sera with defined titers are available for use as internal controls with this kit. Please […]
ID Soft™ is a fully integrated, easy-to-use software program providing convenient, flexible and comprehensive data analysis for IDScreen® poultry ELISA kits. Download the ID Soft™ technical sheet Determine titres, vaccination age and baseline values for better preventative medicine for poultry. Easily share your results: OD values may be exported to other formats, such as Excel. Optimize […]
We provide outstanding customer service and technical support thanks to our distribution network spanning all continents. By adapting products to meet your needs, rapidly responding to your queries, providing free supplementary liquid reagents, and assisting you in kit use and result interpretation, IDvet is with you at every step.